Antithrombin III Activity Test

Your blood has a built-in safety system that prevents clots from forming where they are not needed. The central player in that system is antithrombin (historically called antithrombin III), a protein responsible for roughly 60 to 80 percent of your blood's natural clot-blocking activity. When antithrombin is low, your blood tips toward excessive clotting, and the consequences can be severe: deep vein thrombosis, pulmonary embolism, or clots in unusual locations like the veins of the intestine.

What makes this test especially valuable is that antithrombin deficiency is the most dangerous of the inherited clotting disorders, carrying a risk of venous blood clots more than 20 times higher than normal. Yet it never appears on a routine blood panel. You could have perfectly normal results on every standard test and still be walking around with a clotting system that is quietly out of balance.

How Antithrombin Works

Antithrombin belongs to a family of proteins called serine protease inhibitors (serpins). Its job is to latch onto activated clotting enzymes, especially thrombin and factor Xa, and permanently shut them down by forming a tight one-to-one complex that the liver then clears from the blood. Without antithrombin, these enzymes would keep driving clot formation unchecked.

This is also the reason heparin, one of the most widely used blood-thinning medications, works at all. Heparin binds to antithrombin and speeds up its clot-blocking activity by roughly a thousand fold. If your antithrombin level is too low, heparin cannot do its job, a situation doctors call heparin resistance. This makes the antithrombin activity test uniquely useful: it is the only natural anticoagulant test that also predicts whether heparin will work for you.

Hereditary Deficiency

Inherited antithrombin deficiency affects roughly 1 in 2,000 to 5,000 people and follows a dominant inheritance pattern, meaning you only need one affected copy of the gene (SERPINC1) to be at risk. Over 250 different mutations have been identified. Deficiency comes in two forms: Type I, where your body simply makes too little of the protein, and Type II, where you make normal amounts but the protein does not function properly.

The clinical picture of hereditary deficiency is striking. About half of carriers experience a clotting event by age 50, often without any obvious trigger. Roughly 60% of these events occur spontaneously. The most common sites are deep veins of the legs and lungs, but the intestinal veins are particularly vulnerable. On the other hand, about half of people who carry a deficiency-causing mutation never develop a clot in their lifetime, which is why knowing your status matters: it lets you and your doctor prepare for high-risk moments like surgery, pregnancy, or prolonged immobility.

Venous Blood Clot Risk

Antithrombin deficiency carries the highest clotting risk among the inherited thrombophilias. A study of 823 patients with a first venous blood clot found that those with antithrombin activity below 70% had a recurrence rate of 3.53% per year. The risk was dose-dependent: activity between 70 and 80% carried about a 2.4 times higher risk of recurrence compared to levels above 80%.

The MEGA follow-up study tracked 2,357 patients after a first clot for a median of 7.4 years. Those with antithrombin activity below the 5th percentile of the study population had a 1.5 times higher risk of recurrence. Below 80% activity, the risk jumped to 3.7 times higher. This association held regardless of whether the original clot had an identifiable trigger.

Pregnancy Risks

Pregnancy is one of the highest-risk periods for anyone with antithrombin deficiency. A systematic review and meta-analysis of multiple studies found an absolute clot risk of 7.3% during pregnancy and 11.1% in the weeks after delivery for women with antithrombin deficiency. Risk varies dramatically with severity: women with mild deficiency (70 to 85% activity) and no prior clotting history face a risk of only 0.2 to 0.4%, while those with severe deficiency and a history of clots face risks as high as 40%.

Antithrombin levels naturally fall during pregnancy, dropping roughly 20% below baseline, with the sharpest decline occurring at delivery. Levels bottom out about 12 hours after birth and typically return to baseline within 72 hours. This normal pregnancy-related drop can push someone with borderline levels into a clearly deficient range, which is why knowing your baseline before pregnancy is so valuable.

Heart and Arterial Disease

While antithrombin deficiency primarily affects veins rather than arteries, emerging evidence suggests a connection to arterial events in younger people. A study combining a case-control analysis (571 patients with premature arterial clots, 461 controls) with a nested cohort (323 coronary heart disease patients) found that antithrombin levels at or below the median were associated with a 1.46 times higher risk of a first arterial clot. Among those who already had coronary disease, low antithrombin predicted a 2.16 times higher risk of recurrent cardiac events. In women specifically, the risk was nearly 6 times higher.

A separate 9-year study of 209 patients with chest pain from narrowed heart arteries (angina) found that each standard-deviation decrease in antithrombin activity was associated with a 25% higher risk of heart attack or cardiac death, independent of other cardiac risk factors.

Antithrombin in Critical Illness

Low antithrombin is a strong prognostic signal in several acute conditions. In patients hospitalized with severe flare-ups of chronic lung disease (COPD), antithrombin activity below roughly 80% predicted a 4.5 times higher risk of death, independent of other inflammatory markers. In patients with acute liver failure from hepatitis B, antithrombin activity predicted 30-day mortality with an area under the curve of 0.80, meaning it performed well as a prognostic tool. Among trauma patients, antithrombin deficiency occurred in 30 to 62% of cases, with the highest rates in the first 24 hours.

These findings in critically ill populations reflect acquired deficiency, where the liver cannot keep up with demand, proteins leak through damaged blood vessels, or clotting factors are consumed faster than they can be replaced. For someone ordering this test proactively, the takeaway is that antithrombin levels serve as a sensitive barometer of how well your liver and clotting system are functioning under stress.

Reference Ranges

Antithrombin activity is measured using a lab technique that tests how well the protein works (a chromogenic functional assay) and reported as a percentage of a standard reference. A large study of 9,669 healthy blood donors found a mean of 105.6% with a standard deviation of 11.2%. The standard adult reference range is 80 to 120%. Several factors shift where you fall within that range: women generally have higher levels than men, levels rise in women after menopause, and oral contraceptive use can lower levels by roughly 4 percentage points.

These tiers are drawn from published research and clinical guidelines. Your lab may use slightly different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. A single reading below 80% does not diagnose hereditary deficiency on its own; acquired causes must be ruled out first.

Activity vs. Antigen: Why the Test Type Matters

This test measures antithrombin activity, meaning how well the protein actually works, not just how much of it is present. This distinction matters because some people make normal amounts of antithrombin that does not function properly (Type II deficiency). An antigen test, which measures protein quantity, would look normal in those individuals. The International Society on Thrombosis and Haemostasis recommends that initial testing always use an activity assay for this reason.

If your activity level comes back low, the next step is an antigen test. Comparing the two results helps distinguish between Type I deficiency (both low) and Type II deficiency (normal antigen, low activity). This classification has practical implications because certain Type II subtypes, particularly those affecting the heparin-binding region of the protein, may not carry the same elevated clotting risk.

When Results Can Be Misleading

Not every low reading means you have a deficiency. The most common reason for a falsely low result is testing at the wrong time. Active blood clots consume antithrombin, so testing during or shortly after a clotting event can produce artificially low readings. Wait at least six weeks after an acute clot before testing. Similarly, major surgery, sepsis, and severe illness all drive antithrombin down temporarily through increased consumption and reduced liver production.

Several widely used medications also interfere with results. Unfractionated heparin causes a progressive decline of roughly 30% during continuous infusion, though levels return to normal two to three days after stopping. Oral contraceptives lower activity by 20 to 39% depending on the formulation, primarily driven by the estrogen component. If you are taking either, your doctor should account for this when interpreting your result.

Direct oral anticoagulants (DOACs) create a different kind of interference. Rivaroxaban, apixaban, and edoxaban cause falsely elevated results when the lab uses a factor Xa-based assay, while dabigatran interferes with thrombin-based assays. If you are taking a DOAC, make sure your lab knows so they can choose the right assay type. Argatroban and bivalirudin can also produce misleadingly normal or elevated readings.

A 2026 study examining five commercial antithrombin activity assays found that diagnostic sensitivity ranged from 36.8% to 100%, with some assays completely missing certain Type II mutations. This means a normal result does not fully exclude deficiency in every case, particularly for mutations affecting the heparin-binding site. If clinical suspicion is high despite a normal result, testing with a different assay methodology may be warranted.

Tracking Your Trend

A single antithrombin reading is a starting point, not a verdict. The intra-individual coefficient of variation for this test is low, roughly 3.8 to 4.8%, which means your level is quite stable over time when you are healthy. That stability is actually what makes trending so useful: a genuine downward drift stands out clearly against a tight baseline.

If your first result is normal, a repeat in 12 months confirms your baseline. If it is low, the priority is ruling out acquired causes (liver disease, kidney protein loss, medications, recent illness) and retesting on a fresh specimen. The diagnosis of hereditary deficiency should never rest on a single low reading. Once confirmed, tracking annually helps you and your doctor gauge whether levels are stable or drifting, especially around high-risk events like planned surgeries, pregnancies, or changes in medication.

If you are managing a known deficiency, trending becomes even more valuable before and after high-risk situations. Knowing your personal baseline lets you anticipate when you might need antithrombin concentrate replacement, rather than discovering the problem when heparin fails to work during surgery.